Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
508.66B
Market cap508.66B
Price-Earnings ratio
19.73
Price-Earnings ratio19.73
Dividend yield
2.51%
Dividend yield2.51%
Average volume
6.83M
Average volume6.83M
High today
$210.50
High today$210.50
Low today
$203.85
Low today$203.85
Open price
$205.45
Open price$205.45
Volume
11.79M
Volume11.79M
52 Week high
$215.19
52 Week high$215.19
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $210.23. The company's market cap stands at 508.66B, with a P/E ratio of 19.73 and a dividend yield of 2.5%.

On 2026-01-12, Johnson & Johnson(JNJ) stock traded between a low of $203.85 and a high of $210.50. Shares are currently priced at $210.23, which is +3.1% above the low and -0.1% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 11.79M, against a daily average of 6.83M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $215.19 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $215.19 at its peak.

JNJ News

Benzinga 11h
Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

On Saturday, Johnson & Johnson (NYSE:JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantam...

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
TipRanks 1d
J&J announces new longer follow-up results from Phase 1b/2 OrigAMI-1 study

Johnson & Johnson announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody...

24/7 Wall St. 3d
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Eli Lilly (NYSE:...

Analyst ratings

56%

of 27 ratings
Buy
55.6%
Hold
40.7%
Sell
3.7%

More JNJ News

TipRanks 4d
Johnson & Johnson price target raised to $208 from $193 at Bernstein

Bernstein analyst Lee Hambright raised the firm’s price target on Johnson & Johnson to $208 from $193 and keeps a Market Perform rating on the shares. After a l...

Barron's 4d
Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Biotech and Pharma Johnson & Johnson Strikes Deal With White House to Lower Drug Prices In this article JNJ NOVN MRK GSK Johnson & Johnson agrees to lower price...

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices
The Wall Street Journal 4d
Stocks to Watch Friday: GM, Rio Tinto, Glencore

↘️ General Motors (GM) : The carmaker said it would book a $6 billion charge on its money-losing electric-vehicle business. Shares dropped 1.4% in offhours trad...

Stocks to Watch Friday: GM, Rio Tinto, Glencore
Benzinga 4d
Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts

Johnson & Johnson (NYSE:JNJ) struck a deal with the Trump administration on Thursday to lower drug prices for U.S. consumers in exchange for exemptions from tar...

Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts
Nasdaq 4d
Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption

(RTTNews) - Drug major Johnson & Johnson has announced an agreement with the Trump Administration to lower drug prices, enabling millions of Americans to access...

Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption
TipRanks 4d
Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal

Johnson & Johnson (JNJ) reached a significant agreement with the Trump administration to lower drug prices for Americans while securing exemptions from U.S. tar...

The Wall Street Journal 4d
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

J&J’s agreement with the Trump administration follows similar drug-pricing deals between the administration and other pharmaceutical companies. Maxim Shemetov/R...

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.